Together with the new insight in TRAIL-resistance mechanism by DR5-coated EVs, TRAIL treatment in combination with inhibitors preventing secretion of EVs could be a promising combination strategy to treat TRAIL-resistant cancer cells. The gene discussed is TNFRSF10B; the disease is cancer.